HONG KONG – Chugai Pharmaceutical Co. Ltd., of Tokyo, said its Alecensa (alectinib), an anaplastic lymphoma kinase (ALK) inhibitor, gained expanded approved as a first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC) in Taiwan.